Pediatric Hematology/Oncology

Langerhans Cell Histiocytosis

Questions discussed in this category

In the era of MEK inhibitors and BRAF V600E-targeted therapy, what is the role of traditional vinorelbine/prednisone in the management of Langerhans cell histiocytosis?

1 Answer available

How would you approach langerhans cell histiocytosis involving a single bone site after resection?

1 Answer available

Do you recommend using BRAFV600E mutation status to risk stratify treatment for a pediatric patient with langerhans cell histiocytosis?

1 Answer available

Do you recommend using cell-free BRAFV600E to track response to therapy in pediatric patients with langerhans cell histiocytosis?

0 Answers available

Papers discussed in this category

J. Pediatr., 2014 Oct 21

Differentiating skin-limited and multisystem Langerhans cell histiocytosis.

Blood, 2008-03-01

Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification.

Blood, 2013 Jun 20

Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis.

Medical and pediatric oncology, 1994

LCH-I: a randomized trial of etoposide vs. vinblastine in disseminated Langerhans cell histiocytosis. The Histiocyte Society.

Haematologica, 2024 Apr 01

Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders.

Haematologica, 2024 Apr 01

First-line MAPK inhibition in pediatric histiocytosis: are we ready?

Related Topics in Pediatric Hematology/Oncology